<DOC>
	<DOCNO>NCT01588145</DOCNO>
	<brief_summary>The main objective study evaluate safety tolerability HM61713 .</brief_summary>
	<brief_title>Phase I/II Trial Evaluate Safety , Tolerability Pharmacokinetic Profile HM61713 NSCLC Patients</brief_title>
	<detailed_description>Besides main objective , 3 objective follow : - To evaluate anti-cancer effect HM61713 NSCLC patient EGFR mutation - To investigate pharmacokinetic profile HM61713 metabolites oral administration - To investigate biomarkers related safety efficacy HM61713</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Patients histologically cytologically confirm diagnosis advance NSCLC Patients EGFR mutationpositive tumor Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 2 le Estimated life expectancy least 12 week Subjects adequate bone marrow ( WBC ≥4,000/mm3 , Platelet ≥100,000/mm3 , Hemoglobin≥9.0g/dL , ANC≥1,500/mm3 ) , renal ( Creatinine≤1.5 mg/dl ) hepatic [ aspartate aminotransferase ( AST ) / alanine aminotransferase ( ALT ) / alkaline phosphatase ( ALP ) ≤3 x ULN , Total bilirubin ≤2.0 mg/dL ] function . No significant heart lung disease . ※ For subject liver metastasis , AST/ALT/ALP≤ 5 x ULN allow ; subject bone marrow metastasis , ALP≤ 5 x ULN allow Patients amylase level ≤ 1.5 x ULN Subjects provide voluntary consent participate study , sign write consent document &lt; Dose escalation part &gt; Malignancy progress least two prior chemotherapy regimen , include EGFRTKI &lt; Expansion part 1 &gt; Patients disease progression despite anticancer therapy EGFRTKI ( e.g. , erlotinib , gefitinib , neratinib , afatinib , dacomitinib ) Patients provide voluntary consent collection tumor tissue take archive last anticancer therapy collection new tissue specimen sign write consent document &lt; Expansion part 2 &gt; &amp; &lt; Phase 2 &gt; Patients disease progression despite anticancer therapy EGFR TKI ( e.g. , erlotinib , gefitinib , neratinib , afatinib , dacomitinib ) ( Except treatment EGFR mutation selective inhibitor , class drug investigational drug study ) T790M mutationpositive confirm tissue collect PD confirm last anticancer therapy At least one measurable target lesion allow repeat measurement accord RECIST ver1.1 screen &lt; Phase 1 Expansion part 3 &gt; Patients disease progression despite anticancer therapy EGFR TKI ( e.g. , erlotinib , gefitinib , neratinib , afatinib , dacomitinib ) ( Except treatment EGFR mutation selective inhibitor , class drug investigational drug study ) T790M mutationnegative confirm tissue collect progressive disease ( PD ) confirm last anticancer therapy At least one measurable target lesion allow repeat measurement accord RECIST ver1.1 screen Hematologic malignancy Symptomatic uncontrolled central nervous system metastases Interstitial lung disease , include pulmonary fibrosis LVEF &lt; 40 % NYHA Class III IV heart failure History pancreatitis History current evidence , psychiatric congenital disorder , include dementia epilepsy Compromised organ function , infection allergy Pregnant breastfeeding woman , woman childbearing potential use appropriate method contraception ( male patient also use appropriate method contraception study period ) Patients receive investigational product within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>HM61713</keyword>
	<keyword>EGFR-TKI</keyword>
	<keyword>Phase II</keyword>
	<keyword>olmutinib</keyword>
</DOC>